The French animal health company posted €318 million ($339M) in revenue driven by the performance of Asia-Pacific, Europe and Latin America.
In the first 3 months of 2022, the company earned 16.2% than the same period of 2021 mainly driven by “very good double-digit growth” in the petfood, dermatology and hygiene ranges, as well as vaccines for dogs and cats.
In Asia-Pacific, the rate of growth was 22.5% at constant exchange rates. Australia and India were the main drivers of this growth in the area, generating nearly 80% of it, offsetting the decline in China, impacted by Covid-19.
In Europe, revenue grew by 10.4% at real rates thanks to the momentum of the company in France, Italy, the United Kingdom and Germany.
In the United States, revenue in Q1 increased by 17.5% thanks to strong sales.
Virbac is expanding the revenue growth outlook for 2022 at constant rates and scope to a range of between 5% and 10% despite the current “significant” production, logistical and supply constraints.
